CRIS Current Research Information System

CLISSA, CRISTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.218
NA - Nord America 2.146
EU - Europa 1.908
AF - Africa 196
SA - Sud America 87
OC - Oceania 2
Totale 6.557
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.094
SG - Singapore 648
CN - Cina 616
VN - Vietnam 516
GB - Regno Unito 454
IT - Italia 386
SE - Svezia 297
DE - Germania 212
HK - Hong Kong 123
IN - India 106
FR - Francia 99
RU - Federazione Russa 90
BR - Brasile 63
IE - Irlanda 58
KR - Corea 55
NL - Olanda 55
GR - Grecia 48
TG - Togo 46
SC - Seychelles 42
ZA - Sudafrica 40
CA - Canada 35
FI - Finlandia 35
NG - Nigeria 34
EE - Estonia 30
UA - Ucraina 30
JP - Giappone 22
JO - Giordania 21
AT - Austria 20
CH - Svizzera 19
HR - Croazia 19
BE - Belgio 18
CI - Costa d'Avorio 18
BG - Bulgaria 17
BD - Bangladesh 15
PH - Filippine 12
AR - Argentina 11
IR - Iran 10
MY - Malesia 9
MX - Messico 8
PL - Polonia 7
TH - Thailandia 7
TM - Turkmenistan 7
MU - Mauritius 6
PK - Pakistan 6
TR - Turchia 6
EC - Ecuador 5
ES - Italia 5
ID - Indonesia 5
IL - Israele 5
LT - Lituania 5
BB - Barbados 4
SA - Arabia Saudita 4
TW - Taiwan 4
AZ - Azerbaigian 3
IQ - Iraq 3
LB - Libano 3
OM - Oman 3
UZ - Uzbekistan 3
CY - Cipro 2
EG - Egitto 2
ET - Etiopia 2
KE - Kenya 2
KG - Kirghizistan 2
PE - Perù 2
PY - Paraguay 2
TN - Tunisia 2
AU - Australia 1
BS - Bahamas 1
BZ - Belize 1
CO - Colombia 1
DM - Dominica 1
DO - Repubblica Dominicana 1
GI - Gibilterra 1
GY - Guiana 1
HN - Honduras 1
KH - Cambogia 1
LU - Lussemburgo 1
MA - Marocco 1
MK - Macedonia 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
QA - Qatar 1
SO - Somalia 1
UY - Uruguay 1
VE - Venezuela 1
Totale 6.557
Salva come PNG Salva come JPEG
Città #
Singapore 470
Southend 418
Ashburn 240
Chandler 197
Fairfield 180
Santa Clara 141
Hefei 138
Hong Kong 118
Bologna 117
San Jose 99
Houston 92
Woodbridge 92
Beijing 89
Wilmington 89
Ho Chi Minh City 83
Dong Ket 82
Seattle 80
Ann Arbor 78
Hanoi 77
Princeton 73
Cambridge 67
Dublin 58
Milan 55
Boardman 49
Lomé 46
Seoul 44
Westminster 40
Padova 37
Nanjing 36
New York 34
Lauterbourg 33
Helsinki 29
Saint Petersburg 27
Abeokuta 26
Medford 24
Amman 21
Frankfurt am Main 21
Los Angeles 21
Abidjan 18
Brussels 18
Buffalo 18
Jinan 18
Berlin 17
Sofia 17
Changsha 16
Shenyang 16
Tokyo 16
Turin 16
Bern 15
Dallas 15
Jiaxing 14
Redwood City 14
Vienna 14
Bengaluru 13
Da Nang 13
Shanghai 13
Athens 12
Haiphong 12
Hebei 12
Munich 12
Nanchang 12
Redondo Beach 12
Montreal 11
Bremen 10
Tappahannock 10
Toronto 10
Council Bluffs 9
Florence 9
Orem 9
Rome 9
Tianjin 9
Amsterdam 8
Dearborn 8
Grafing 8
Guangzhou 8
Haikou 8
Norwalk 8
San Diego 8
Valsamoggia 8
Falkenstein 7
Hangzhou 7
Zhengzhou 7
Falls Church 6
Jacksonville 6
Kuala Lumpur 6
Mahé 6
North York 6
Tallinn 6
Tongling 6
Turku 6
Bühl 5
Davao City 5
Istanbul 5
Johannesburg 5
São Paulo 5
Wuhan 5
Yubileyny 5
Andover 4
Bangkok 4
Bridgetown 4
Totale 4.240
Salva come PNG Salva come JPEG
Nome #
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 351
Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes 282
EFFICACY, FEASIBILITY AND SAFETY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 272
Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients 272
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience 262
Molecular Characterization of High-Risk MDS Patients Treated with Azacitidine and Lenalidomide: Role of Inositide-Dependent Signalling, Mutations and Microrna 226
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 223
Strategic Role of Nuclear Inositide Signalling in Myelodysplastic Syndromes Therapy 218
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 217
CLINICAL OUTCOME OF T-ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (T-ALL/TLBL): THE BOLOGNA EXPERIENCE 209
Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients 207
An increased expression of PI-PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes 206
Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients 201
DIFFERENTIAL EFFECT OF LENALIDOMIDE ON INDUCTION OF INOSITIDE-DEPENDENT ERYTHROPOIESIS AND CELL CYCLE IN MYELODYSPLASTIC SYNDROMES 196
Computed tomographic pulmonary angiography for diagnosis of invasive mold diseases in patients with hematological malignancies 195
EFFICACY AND CLINICAL OUTCOME OF PHILADELPHIA (PH) POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS TREATED WITH SECOND GENERATION TYROSINE KINASE INHIBITORS (TKIS): THE BOLOGNA EXPERIENCE 189
Epigenetic regulation of nuclear inositide signalling in high-risk MDS patients 186
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 179
Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients 173
Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes 173
Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study 161
CLONAL ACTIVATION OF AKT IN LOW-RISK MDS PATIENTS WITH DEL(5Q) TREATED WITH LENALIDOMIDE 160
Epigenetic Regulation of Lipid Signalling Pathways In Low-Risk MDS Patients During Azacitidine Treatment 158
Nuclear inositide signaling in myelodysplastic syndromes. 151
Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia. 140
Nuclear PI-PLC β1 and Myelodysplastic Syndromes: From Bench to Clinics 138
Nelarabine is safe and effective in adult relapsed or refractory T cellacute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL): The Bologna experience 137
Nelarabine Is Safe and Effective In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL): The Bologna Experience 127
NELARABINE FRONT-LINE THERAPY FOR ADULT T-LYMPHOBLASTIC LEUKAEMIA/LYMPHOMA (T-LBL/ALL): PRELIMINARY RESULTS OF BOLOGNA EXPERIENCE 126
RASGRP1/APTX ratio is a strong biomarker which predicts response to therapy with Tipifarnib plus Bortezomib in elderly patients with Acute Myeloid Leukemia (AML) 126
NELARABINE IS SAFE AND EFFECTIVE IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) AND LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 126
Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients. 125
[Molecular biology in myelodysplastic syndromes and acute myeloid leukemias "smoldering"] 122
Nuclear translocation of PKC-alpha is associated with cell cycle arrest and erythroid differentiation in myelodysplastic syndromes (MDSs) 113
null 103
PI-PLCbeta1 Expression in Patients with High-Risk Myelodysplastic Syndromes Is Affected by Azacitidine Treatment. 103
null 71
Real life use of ravulizumab in Italian patients with paroxysmal nocturnal hemoglobinuria: evidence from the REACTION observational study 44
Totale 6.668
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.651
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.651
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021221 0 0 0 0 0 0 0 0 0 0 9 212
2021/2022778 84 11 52 86 78 48 19 38 39 72 120 131
2022/2023881 72 127 43 114 73 65 31 92 144 9 73 38
2023/2024296 7 41 20 30 40 62 9 18 20 18 16 15
2024/2025832 36 69 71 49 173 50 53 31 3 54 52 191
2025/20262.009 193 211 170 139 246 97 227 86 393 214 33 0
Totale 6.668